KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Receivables (2016 - 2022)

TherapeuticsMD's Receivables history spans 13 years, with the latest figure at $32.2 million for Q3 2022.

  • For Q3 2022, Receivables fell 14.02% year-over-year to $32.2 million; the TTM value through Sep 2022 reached $32.2 million, down 14.02%, while the annual FY2021 figure was $36.2 million, 11.72% up from the prior year.
  • Receivables reached $32.2 million in Q3 2022 per TXMD's latest filing, down from $45.8 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $45.8 million in Q2 2022 to a low of $5.1 million in Q1 2018.
  • Average Receivables over 5 years is $24.1 million, with a median of $24.1 million recorded in 2020.
  • Peak YoY movement for Receivables: surged 226.75% in 2019, then decreased 14.02% in 2022.
  • A 5-year view of Receivables shows it stood at $11.1 million in 2018, then skyrocketed by 120.5% to $24.4 million in 2019, then skyrocketed by 32.74% to $32.4 million in 2020, then rose by 11.72% to $36.2 million in 2021, then dropped by 11.11% to $32.2 million in 2022.
  • Per Business Quant, the three most recent readings for TXMD's Receivables are $32.2 million (Q3 2022), $45.8 million (Q2 2022), and $35.4 million (Q1 2022).